INTS · Intensity Therapeutics, Inc.

Summary

Intensity Therapeutics, Inc. filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock, effective at 4:01 p.m. ET on February 18, 2026, with trading on a post-split basis beginning February 19, 2026 on Nasdaq under ticker INTS and new CUSIP 45828J 202. The split reduces outstanding shares from approximately 63,346,579 to 2,533,863 without changing authorized shares, to regain compliance with Nasdaq's minimum bid price requirement.

Key takeaways

• Filed Certificate of Amendment on February 13, 2026 with Delaware Secretary of State
• 1-for-25 reverse stock split effective 4:01 p.m. ET February 18, 2026
• Post-split trading begins February 19, 2026 on Nasdaq Capital Market under INTS
• Outstanding shares reduce from 63,346,579 (as of February 12, 2026) to approximately 2,533,863
• Cash in lieu of fractional shares based on February 18, 2026 closing price adjusted for split
• New CUSIP 45828J 202; proportionate adjustments to options, warrants, and incentive plans